RECURSION PHARMACEUTICALS, INC. (RXRX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 119.89M USD | Liabilities, Current |
| Cash and equivalents | 545.68M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $119.89M | $545.68M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $129.70M | $654.47M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $147.71M | $743.29M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $155.10M | $659.84M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $164.03M | $525.11M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $141.98M | $500.45M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $187.47M | $594.35M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $108.89M | $427.65M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $86.08M | $474.34M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $73.92M | $296.33M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $93.17M | $391.56M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $94.12M | $387.32M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $113.96M | $405.87M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $92.15M | $473.14M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $100.27M | $549.91M | (m) | $0.00 | (m) | (m) |
| 2022-09-30 | (m) | $83.04M | $454.65M | (m) | $0.00 | (m) | (m) |
| 2022-06-30 | (m) | $96.65M | $453.88M | (m) | $21.00K | (m) | (m) |
| 2022-03-31 | (m) | $85.70M | $507.89M | (m) | $34.00K | (m) | (m) |
| 2021-12-31 | (m) | $46.66M | $285.12M | (m) | $34.00K | (m) | (m) |
| 2021-09-30 | (m) | $42.94M | $394.72M | (m) | $34.00K | (m) | (m) |
| 2021-06-30 | (m) | $29.54M | $632.74M | (m) | $49.00K | (m) | (m) |
| 2021-03-31 | (m) | $26.85M | $214.09M | (m) | $71.00K | (m) | (m) |
| 2020-12-31 | (m) | $23.10M | $262.13M | (m) | $156.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |